G. Viale, The current state of breast cancer classification, Annals of Oncology, vol.23, issue.suppl 10, pp.207-210
DOI : 10.1093/annonc/mds326

C. Perou, T. Sørlie, M. Eisen, M. Van-de-rijn, S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000.
DOI : 10.1038/35021093

L. Veer, . V-'t, H. Dai, M. Van-de-vijver, Y. He et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, issue.6871, pp.530-536, 2002.
DOI : 10.1038/415530a

T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001.
DOI : 10.1073/pnas.191367098

Z. Hu, C. Fan, D. Oh, J. Marron, X. He et al., The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, vol.7, issue.1, p.96, 2006.
DOI : 10.1186/1471-2164-7-96

P. Farmer, H. Bonnefoi, V. Becette, M. Tubiana-hulin, P. Fumoleau et al., Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, vol.268, issue.29, pp.4660-4671, 2005.
DOI : 10.1023/A:1006356502820

B. Lehmann, J. Bauer, X. Chen, M. Sanders, A. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Journal of Clinical Investigation, vol.121, issue.7
DOI : 10.1172/JCI45014DS1

J. Herschkowitz, K. Simin, V. Weigman, I. Mikaelian, J. Usary et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biology, vol.8, issue.5, p.76, 2007.
DOI : 10.1186/gb-2007-8-5-r76

A. Prat, J. Parker, O. Karginova, C. Fan, C. Livasy et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Research, vol.15, issue.1, p.68, 2010.
DOI : 10.1038/nm0809-842

C. Creighton, X. Li, M. Landis, J. Dixon, V. Neumeister et al., Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proceedings of the National Academy of Sciences, vol.106, issue.33, pp.13820-13825, 2009.
DOI : 10.1073/pnas.0905718106

M. Van-de-vijver, Y. He, . Van-'t, L. Veer, H. Dai et al., A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002.
DOI : 10.1056/NEJMoa021967

M. Schmidt, D. Böhm, C. Von-törne, E. Steiner, A. Puhl et al., The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer, Cancer Research, vol.68, issue.13, pp.5405-5413, 2008.
DOI : 10.1158/0008-5472.CAN-07-5206

Y. Wang, J. Klijn, Y. Zhang, A. Sieuwerts, M. Look et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, The Lancet, vol.365, issue.9460, pp.671-679, 2005.
DOI : 10.1016/S0140-6736(05)70933-8

C. Sotiriou, P. Wirapati, S. Loi, A. Harris, S. Fox et al., Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis, JNCI Journal of the National Cancer Institute, vol.98, issue.4, pp.262-272, 2006.
DOI : 10.1093/jnci/djj052

A. Ivshina, J. George, O. Senko, B. Mow, T. Putti et al., Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer, Cancer Research, vol.66, issue.21, pp.10292-10301, 2006.
DOI : 10.1158/0008-5472.CAN-05-4414

C. Desmedt, F. Piette, S. Loi, Y. Wang, F. Lallemand et al., Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series, Clinical Cancer Research, vol.13, issue.11, pp.3207-3214, 2007.
DOI : 10.1158/1078-0432.CCR-06-2765

L. Miller, J. Smeds, J. George, V. Vega, L. Vergara et al., From The Cover: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival, Proceedings of the National Academy of Sciences, vol.102, issue.38, pp.13550-13555, 2005.
DOI : 10.1073/pnas.0506230102

K. Hess, K. Anderson, W. Symmans, V. Valero, N. Ibrahim et al., Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, vol.24, issue.26
DOI : 10.1200/JCO.2006.05.6861

H. Bonnefoi, A. Potti, M. Delorenzi, L. Mauriac, M. Campone et al., Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994, Lancet Oncol, vol.8, pp.0-01, 2007.

M. Guedj, L. Marisa, A. De-reynies, B. Orsetti, R. Schiappa et al., A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2012.
DOI : 10.1038/nature09515
URL : https://hal.archives-ouvertes.fr/inserm-00611752

C. Desmedt, D. Leo, A. De-azambuja, E. Larsimont, D. Haibe-kains et al., Multifactorial Approach to Predicting Resistance to Anthracyclines, Journal of Clinical Oncology, vol.29, issue.12, pp.1578-1586, 2011.
DOI : 10.1200/JCO.2010.31.2231

L. Korde, L. Lusa, L. Mcshane, P. Lebowitz, L. Lukes et al., Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer, Breast Cancer Research and Treatment, vol.99, issue.22, pp.685-699, 2010.
DOI : 10.1007/s10549-009-0651-3

A. Minn, G. Gupta, P. Siegel, P. Bos, W. Shu et al., Genes that mediate breast cancer metastasis to lung, Nature, vol.436, issue.7050, pp.518-524, 2005.
DOI : 10.1038/nature03799

W. Miller, A. Larionov, L. Renshaw, T. Anderson, S. White et al., Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole, Pharmacogenetics and Genomics, vol.17, issue.10, pp.813-826, 2007.
DOI : 10.1097/FPC.0b013e32820b853a

A. Klein, R. Wessel, M. Graessmann, M. Jürgens, I. Petersen et al., Comparison of gene expression data from human and mouse breast cancers: Identification of a conserved breast tumor gene set, International Journal of Cancer, vol.37, issue.3, pp.683-688, 2007.
DOI : 10.1002/ijc.22630

K. Hoeflich, O. Brien, C. Boyd, Z. Cavet, G. Guerrero et al., In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models, Clinical Cancer Research, vol.15, issue.14, pp.4649-4664, 2009.
DOI : 10.1158/1078-0432.CCR-09-0317

B. Marty, V. Maire, E. Gravier, G. Rigaill, A. Vincent-salomon et al., Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells, Breast Cancer Research, vol.22, issue.6, p.101, 2008.
DOI : 10.1093/bioinformatics/btl359

K. Chin, S. Devries, J. Fridlyand, P. Spellman, R. Roydasgupta et al., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies, Cancer Cell, vol.10, issue.6, pp.529-541, 2006.
DOI : 10.1016/j.ccr.2006.10.009

K. Yu, K. Ganesan, L. Tan, M. Laban, J. Wu et al., A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers, PLoS Genetics, vol.4, issue.7, p.1000129, 2008.
DOI : 10.1371/journal.pgen.1000129.s012

P. Bos, X. Zhang, C. Nadal, W. Shu, R. Gomis et al., Genes that mediate breast cancer metastasis to the brain, Nature, vol.6, issue.7249, pp.1005-1009, 2009.
DOI : 10.1038/nature08021

Y. Zhang, A. Sieuwerts, M. Mcgreevy, G. Casey, T. Cufer et al., The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy, Breast Cancer Research and Treatment, vol.62, issue.2, pp.303-309, 2009.
DOI : 10.1007/s10549-008-0183-2
URL : https://hal.archives-ouvertes.fr/hal-00478265

W. Barry, D. Kernagis, H. Dressman, R. Griffis, J. Hunter et al., Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome, Journal of Clinical Oncology, vol.28, issue.13, pp.2198-2206, 2010.
DOI : 10.1200/JCO.2009.26.7245

D. Chen, A. Nasir, A. Culhane, C. Venkataramu, W. Fulp et al., Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue, Breast Cancer Research and Treatment, vol.122, issue.7, pp.335-346, 2010.
DOI : 10.1007/s10549-009-0344-y

V. Popovici, W. Chen, B. Gallas, C. Hatzis, W. Shi et al., Effect of training-sample size and classification difficulty on the accuracy of genomic predictors, Breast Cancer Research, vol.2, issue.1, p.5, 2010.
DOI : 10.1186/1471-2105-7-235

T. Iwamoto, G. Bianchini, D. Booser, Y. Qi, C. Coutant et al., Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer, JNCI Journal of the National Cancer Institute, vol.103, issue.3, pp.264-272, 2011.
DOI : 10.1093/jnci/djq524

A. Tabchy, V. Valero, T. Vidaurre, A. Lluch, H. Gomez et al., Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer, Clinical Cancer Research, vol.16, issue.21, pp.5351-5361, 2010.
DOI : 10.1158/1078-0432.CCR-10-1265

C. Hatzis, L. Pusztai, V. Valero, D. Booser, L. Esserman et al., A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer, JAMA, vol.305, issue.18, pp.1873-1881, 2011.
DOI : 10.1001/jama.2011.593

R. Irizarry, B. Hobbs, C. F. Beazer-barclay, Y. Antonellis, K. Scherf et al., Exploration, normalization, and summaries of high density oligonucleotide array probe level data, Biostatistics, vol.4, issue.2, pp.249-264, 2003.
DOI : 10.1093/biostatistics/4.2.249

J. Parker, M. Mullins, M. Cheang, S. Leung, D. Voduc et al., Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-1167, 2009.
DOI : 10.1200/JCO.2008.18.1370

C. Palmer, M. Diehn, A. Alizadeh, and P. Brown, Cell-type specific gene expression profiles of leukocytes in human peripheral blood, BMC Genomics, vol.7, issue.1, p.115, 2006.
DOI : 10.1186/1471-2164-7-115

J. Taube, J. Herschkowitz, K. Komurov, A. Zhou, S. Gupta et al., Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes, Proceedings of the National Academy of Sciences, vol.107, issue.35, pp.15449-15454, 2010.
DOI : 10.1073/pnas.1004900107

M. Gatza, J. Lucas, W. Barry, J. Kim, Q. Wang et al., A pathway-based classification of human breast cancer, Proceedings of the National Academy of Sciences, vol.107, issue.15, pp.6994-6999, 2010.
DOI : 10.1073/pnas.0912708107

E. Lim, F. Vaillant, D. Wu, N. Forrest, B. Pal et al., Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nature Medicine, vol.5, issue.8, pp.907-913, 2009.
DOI : 10.1038/nm.2000

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, New England Journal of Medicine, vol.351, issue.27, pp.2817-2826, 2004.
DOI : 10.1056/NEJMoa041588

G. Bianchini, Y. Qi, R. Alvarez, T. Iwamoto, C. Coutant et al., Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor???Positive and ???Negative Cancers, Journal of Clinical Oncology, vol.28, issue.28, pp.4316-4323, 2010.
DOI : 10.1200/JCO.2009.27.2419

R. Sabatier, P. Finetti, E. Mamessier, S. Raynaud, N. Cervera et al., Kinome expression profiling and prognosis of basal breast cancers, Molecular Cancer, vol.10, issue.1, p.86, 2011.
DOI : 10.1016/S0140-6736(09)60404-9
URL : https://hal.archives-ouvertes.fr/inserm-00614833

A. Rody, U. Holtrich, L. Pusztai, C. Liedtke, R. Gaetje et al., T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast Cancer Research, vol.10, issue.2, p.15, 2009.
DOI : 10.1186/bcr2124

A. Teschendorff, A. Miremadi, S. Pinder, I. Ellis, and C. Caldas, An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer, Genome Biology, vol.8, issue.8, p.157, 2007.
DOI : 10.1186/gb-2007-8-8-r157

P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati et al., A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nature Medicine, vol.57, issue.1, pp.68-74, 2009.
DOI : 10.1186/bcr1608

A. Ertel, J. Dean, H. Rui, C. Liu, A. Witkiewicz et al., RB-pathway disruption in breast cancer, Cell Cycle, vol.62, issue.20, pp.4153-4163, 2010.
DOI : 10.1038/nm.2090

J. Adélaïde, P. Finetti, I. Bekhouche, L. Repellini, J. Geneix et al., Integrated Profiling of Basal and Luminal Breast Cancers, Cancer Research, vol.67, issue.24, pp.11565-11575, 2007.
DOI : 10.1158/0008-5472.CAN-07-2536

R. Beroukhim, G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh et al., Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma, Proceedings of the National Academy of Sciences, vol.104, issue.50, pp.20007-20012, 2007.
DOI : 10.1073/pnas.0710052104

J. Herschkowitz, W. Zhao, M. Zhang, J. Usary, G. Murrow et al., Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells, Proceedings of the National Academy of Sciences, vol.109, issue.8, pp.2778-2783, 2011.
DOI : 10.1073/pnas.1018862108

J. Hicks, A. Krasnitz, B. Lakshmi, N. Navin, M. Riggs et al., Novel patterns of genome rearrangement and their association with survival in breast cancer, Genome Research, vol.16, issue.12, pp.1465-1479, 2006.
DOI : 10.1101/gr.5460106

L. Mcshane, D. Altman, W. Sauerbrei, S. Taube, M. Gion et al., Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK), JNCI Journal of the National Cancer Institute, vol.97, issue.16, pp.1180-1184, 2005.
DOI : 10.1093/jnci/dji237

Y. Gong, K. Yan, F. Lin, K. Anderson, C. Sotiriou et al., Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study, The Lancet Oncology, vol.8, issue.3, pp.203-211, 2007.
DOI : 10.1016/S1470-2045(07)70042-6

D. Fiore, P. Pierce, J. Kraus, M. Segatto, O. King et al., erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells, Science, vol.237, issue.4811, pp.178-182, 1987.
DOI : 10.1126/science.2885917

S. Chandriani, E. Frengen, V. Cowling, S. Pendergrass, C. Perou et al., A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response, PLoS ONE, vol.100, issue.8, p.6693, 2009.
DOI : 10.1371/journal.pone.0006693.s009

F. Bertucci and D. Birnbaum, Genomics and clinical research for breast cancer, Médecine Sci MS 2012, pp.14-18

F. Bertucci, P. Finetti, and D. Birnbaum, Basal Breast Cancer: A Complex and Deadly Molecular Subtype, Current Molecular Medicine, vol.12, issue.1, pp.96-110, 2012.
DOI : 10.2174/156652412798376134